GILEAD SCIENCES, INC. - Mar 18, 2025 Form SCHEDULE 13G/A Schedule Report for Kalaris Therapeutics, Inc.

Filing Manager: GILEAD SCIENCES, INC.
Reporting Manager: GILEAD SCIENCES, INC.
Security: Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value
Shares outstanding: 18.5M shares
Disclosed Ownership: 723K shares
Ownership: 3.9%
Form type: SCHEDULE 13G/A
Date filed: 3/20/2025, 04:32 PM
Date of event: Mar 18, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
GILEAD SCIENCES, INC.	3.9%	723K	723K	0	/s/ Andrew D. Dickinson	Andrew D. Dickinson, Executive Vice President and Chief Financial Officer